Financial Gravity Asset Management, Inc. Incyte Corp Transaction History

Financial Gravity Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$74.18 - $108.93 $370 - $544	-5 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$63.18 - $85.97 $631 - $859	-10 Reduced 66.67%	5 $0
Q4 2019 Feb 28, 2020	SELL	$73.04 - $95.72 $73 - $95	-1 Reduced 6.25%	15 $87,000
Q3 2019 Oct 15, 2019	SELL	$72.82 - $86.52 $8,228 - $9,776	-113 Reduced 87.6%	16 $1,000
Q2 2019 Jul 26, 2019	SELL	$73.52 - $88.7 $33,966 - $40,979	-462 Reduced 78.17%	129 $11,000
Q1 2019 Apr 19, 2019	BUY	$63.56 - $88.17 $36,547 - $50,697	575 Added 3593.75%	591 $51,000
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $60 - $83	-1 Reduced 5.88%	16 $1,000
Q1 2018 May 23, 2018	BUY	$83.06 - $100.98 $1,412 - $1,716	17 New	17 $1,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.